Clene(CLNN)

Focus: Clene is a public nanotherapeutics company focused on gold nanocrystal-based treatments for neurological diseases including multiple sclerosis, ALS, and Parkinson's disease. With 201-500 employees and founded in 2013, the company operates as a clinical-stage biotech with a highly differentiated platform.

Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

201-500

Open Jobs

About Clene

AI assessmentNot Hiring

No open roles listed right now. Follow Clene to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$342K

Pipeline & Clinical Trials

CNM-Au8

ALS

N/A

Clinical Trials (1)

NCT06408727Intermediate Expanded Access Protocol CNMAu8.EAP04

N/A

Help build intelligence for Clene

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering nanotherapeutics platform with potentially first-in-class mechanism of action across multiple high-unmet-need neurological indications
Public company status (NASDAQ: CLNN) provides equity upside and career visibility unavailable at pre-revenue stage
Multiple Phase 2/2b programs across MS and ALS with near-term clinical readouts offering opportunity to work on transformative neurology programs

Watch Out For

Severe financial stress: $39.4M net loss in FY2025 on only $342K revenue with cash declining from $29M to $12M; runway concerns are acute
Zero active job openings and no hiring activity suggests potential restructuring or capital preservation mode limiting growth opportunities
Experimental platform (gold nanocrystals) faces significant clinical validation risk; no approved products provide revenue stability

Generated by Claude from Clene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

CNM-Au8

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT05281484Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

N/A

CNM-Au8

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT04081714Intermediate Expanded Access Protocol CNMAu8.EAP03

N/A

CNM-Au8

Healthy Volunteers - Male and Female

PHASE_1

Clinical Trials (1)

NCT02755870A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers

Phase 1

Gold Nanocrystals

Parkinson's Disease

PHASE_2

Clinical Trials (1)

NCT0381591631P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

Phase 2

CNM-Au8

Amyotrophic Lateral Sclerosis

PHASE_2

Clinical Trials (1)

NCT04098406Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)

Phase 2

CNM-ZnAg

Covid19

PHASE_2

Clinical Trials (1)

NCT04610138Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants

Phase 2

CNM-Au8

Relapsing Remitting Multiple Sclerosis

PHASE_2

Clinical Trials (1)

NCT03536559Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

Phase 2

CNMAu8

Amyotrophic Lateral Sclerosis

PHASE_2

Clinical Trials (1)

NCT05299658An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Phase 2

Gold Nanocrystals

Amyotrophic Lateral Sclerosis

PHASE_2

Clinical Trials (1)

NCT0384371031P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)

Phase 2

gold nanocrystals

Multiple Sclerosis

PHASE_2

Clinical Trials (1)

NCT0399317131P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.

Phase 2

CNM-Au8

Relapsing Multiple Sclerosis

PHASE_2_3

Clinical Trials (1)

NCT04626921A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Phase 2/3

CNM-Au8

Amyotrophic Lateral Sclerosis

PHASE_2_3

Clinical Trials (1)

NCT04414345HEALEY ALS Platform Trial - Regimen C CNM-Au8

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2013

Portfolio: 13 clinical trials

Top TAs: Neurology, Infectious Diseases, Ophthalmology

SEC Filings: 2 available

Therapeutic Area Focus

Neurology

11 pipeline

Infectious Diseases

1 pipeline

Ophthalmology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$342K48%

R&D Spend

$20M(5865%)25%

Net Income

-$39M

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo